NCT06951997

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chidamide, Albumin-bound Paclitaxel and Gemcitabine as First-line Treatment for Metastatic Pancreatic Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.

Conditions

• Metastatic Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	QL1706	5mg/kg, q3w
DRUG	Chidamide	20mg, biw, q3w
DRUG	Gemcitabine	1000mg/m2 Q3W
DRUG	Nab-paclitaxel	125mg/m2 Q3W

Timeline

• Start date: 2025-03-07
• Primary completion: 2027-05-15
• Completion: 2027-12-31
• First posted: 2025-04-30
• Last updated: 2026-01-26

Locations

1 site across 1 country: China